New drugs in melanoma: It's a whole new world

Keyphrases

• New Drugs 100%
• Phase II Trial 100%
• Melanoma 100%
• Ipilimumab 100%
• Dacarbazine 100%
• Monoclonal Antibody 66%
• Antibody Targeting 66%
• Second-line Treatment 66%
• Mitogen-activated Protein Kinase Inhibitor 66%
• Progression-free Survival 33%
• Overall Survival 33%
• Combination Therapy 33%
• Drug Combination 33%
• Pathway Inhibitors 33%
• Adjuvant Therapy 33%
• BRAF V600E mutation 33%
• T Cells 33%
• European Medicines Agency 33%
• Cancer Treatment 33%
• Relapse-free Survival 33%
• Immunomodulation 33%
• Programmed Death-ligand 1 (PD-L1) 33%
• Median Survival 33%
• Survival Benefit 33%
• Systemic Therapy 33%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 33%
• Lymph Node Positive 33%
• Spectacular 33%
• European Organizations 33%
• High Response Rate 33%
• Immunomodulator 33%
• Vemurafenib 33%
• Metastatic Melanoma 33%
• Melanoma Treatment 33%
• BRAF Inhibitor (BRAFi) 33%
• Adjuvant Trials 33%
• Pegylated Interferon 33%
• Advanced Melanoma 33%
• Planning Phase 33%
• V-raf murine Sarcoma Viral Oncogene Homolog B1 33%
• Sustained Impact 33%

Medicine and Dentistry

• Melanoma 100%
• Ipilimumab 60%
• Dacarbazine 60%
• Monoclonal Antibody 40%
• Mitogen Activated Protein Kinase Inhibitor 40%
• T Cell 20%
• Overall Survival 20%
• Systemic Therapy 20%
• Progression Free Survival 20%
• Medicine 20%
• Combination Therapy 20%
• Cancer Treatment 20%
• Immunomodulating Agent 20%
• Immunomodulation 20%
• Adjuvant Therapy 20%
• Recurrence Free Survival 20%
• Lymph Node 20%
• Vemurafenib 20%
• Metastatic Melanoma 20%
• Peginterferon 20%
• CTLA-4 20%
• Virus Oncogene 20%
• Connective Tissue Cancer 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Ipilimumab 60%
• Dacarbazine 60%
• Monoclonal Antibody 40%
• Mitogen Activated Protein Kinase Inhibitor 40%
• Malignant Neoplasm 20%
• Combination Therapy 20%
• Overall Survival 20%
• Recurrence Free Survival 20%
• Progression Free Survival 20%
• Metastatic Melanoma 20%
• Vemurafenib 20%
• Peginterferon 20%
• Immunomodulating Agent 20%
• Immunomodulation 20%
• Connective Tissue Cancer 20%
• Cytotoxic T Lymphocyte Antigen 4 20%